What the review adds

Moradi et al. integrate two public databases with the USAG-1 literature to argue that the therapeutic target is not uniformly distributed across oral tissues. Using the DISCO human single-cell atlas, they map USAG-1 (SOSTDC1) expression in gingiva to three subsets: CD9+APCDD1+ fibroblasts, CDH19+LAMA2+ fibroblasts, and Krt14+ basal epithelial cells. A STRING protein-protein interaction query then links USAG-1 to LRP5, DKK4, BMP4, BMP7, and BMP2. The authors use this to frame USAG-1 inhibition as a network-level intervention that could influence dentin-pulp regeneration, gingival repair, and alveolar bone remodeling together.

The analytical move is reasonable: if an antibody is going to be delivered locally in the mouth, knowing which resident cells express the target matters. The review does not, however, measure USAG-1 protein levels or validate the cell-type assignment with its own experiments; the gingival map is a reanalysis of existing atlas data.

The preclinical basis it rests on

For the animal evidence, the review cites Murashima-Suginami et al., Science Advances, 2021. That paper reports that anti-USAG-1 monoclonal antibodies which block BMP signaling, but not Wnt coreceptor binding, rescue congenital tooth agenesis in EDA1-deficient mice and generate supernumerary teeth in wild-type mice after a single systemic dose. The same BMP-blocking antibody produced an extra incisor resembling a third dentition in postnatal ferrets, with phosphorylated Smad1/5/8 detectable in the pulp. These are mouse and ferret results, and the ferret work required immunosuppression and a five-fold higher dose than the mouse work. The review accurately summarizes this as a preclinical foundation; it does not establish that the antibody will induce teeth in humans.

The clinical timeline: what is and is not in the record

The review states that a Phase I trial began at Kyoto University Hospital in 2024, with Phase II in congenital tooth agenesis planned for 2026, Phase III around 2028, and commercialization possible by 2030. The public announcement from Kitano Hospital, the trial’s sponsor, confirms only the first part. The first-in-human study is a single-dose, double-blind, randomized, placebo-controlled dose-escalation trial run at Ki-CONNECT within Kyoto University Hospital, with Kitano Hospital as the principal research site. It was approved by PMDA on 25 March 2024, is planned for September 2024 to August 2025, and enrolls men aged 30 to 65 with one or more missing molars. The primary endpoint is safety and tolerability; the subjects are described as healthy volunteers, not patients being treated for tooth loss.

Everything beyond Phase I, including the 2030 commercialization date, is a developer projection or a planning assumption. It is not present in the registry announcement and has not been reported in a peer-reviewed clinical paper.

Where we differ from the coverage

Three points in the review and surrounding coverage deserve a sharper boundary.

First, the trial is often described as a “tooth regrowth” clinical trial. The registry frames it as a first-in-human safety and pharmacokinetic study in healthy adults. Tooth induction in a person is not an endpoint of the posted Phase I protocol.

Second, the 2030 commercialization timeline is repeated as if it were a scheduled milestone. The Kitano Hospital announcement describes a future Phase IIa in children with congenital edentulism and a longer-term aspiration to treat acquired tooth loss; it does not give a commercialization year. The 2030 figure originates with developer communications and has been carried forward without attribution.

Third, the review’s title and abstract refer to “clinical trial data,” but the body correctly notes that no peer-reviewed clinical trial has been published and that media announced the Phase I start. The reader has to look past the abstract to see that the clinical evidence in the paper is the public announcement, not trial results.

What would move the program

The review’s cell-type map is a useful organizing idea, but it is descriptive. For the TRG-035 program, the decisive next step remains the same: a peer-reviewed report of an efficacy endpoint in the intended patient population, children with congenital tooth agenesis, with its statistical analysis plan. Until then, the honest summary is that one antibody has been given to adults for safety, the preclinical mechanism in animals is well documented, and the gingival expression map adds a plausible but unvalidated hypothesis about where the target sits in human oral tissue.

Provenance: every claim traces to Moradi et al. 2026, Murashima-Suginami et al. 2021, the Kitano Hospital trial announcement, or direct STRING queries, per our method at /method/.